tryptophan has been researched along with aprepitant in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coveñas, R; González-Ortega, A; Muñoz, M | 1 |
| Carranza, A; Coveñas, R; González-Ortega, A; Muñoz, M; Robles-Frias, MJ; Rosso, M; Salinas-Martín, MV | 1 |
| Ghabriel, MN; Harford-Wright, E; Lewis, KM; Vink, R | 1 |
| Almendro, V; Carranza, A; Coveñas, R; Garcia-Recio, S; González-Ortega, A; Muñoz, M; Salinas-Martín, MV | 1 |
| Douglas, SD; Evans, DL; Kinder, A; Pappa, V; Rappaport, J; Spitsin, S | 1 |
1 trial(s) available for tryptophan and aprepitant
| Article | Year |
|---|---|
Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV.
Topics: Adult; Anti-HIV Agents; Aprepitant; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Kynurenine; Male; Mood Disorders; Neuroimmunomodulation; Neurokinin-1 Receptor Antagonists; Ritonavir; Treatment Outcome; Tryptophan | 2021 |
4 other study(ies) available for tryptophan and aprepitant
| Article | Year |
|---|---|
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Dose-Response Relationship, Drug; Female; Humans; Inhibitory Concentration 50; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; Receptors, Neurokinin-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Substance P; Tryptophan | 2012 |
The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Topics: Antineoplastic Agents; Apoptosis; Aprepitant; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Structure-Activity Relationship; Substance P; Tryptophan; Tumor Cells, Cultured | 2012 |
NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Astrocytes; Brain Edema; Brain Neoplasms; Calcium-Binding Proteins; Carcinoma; Cell Line, Tumor; Corpus Striatum; Dexamethasone; Drug Screening Assays, Antitumor; Female; Glial Fibrillary Acidic Protein; Humans; In Vitro Techniques; Male; Mammary Neoplasms, Experimental; Microfilament Proteins; Microglia; Models, Biological; Morpholines; Neoplasm Proteins; Neurokinin-1 Receptor Antagonists; Random Allocation; Rats; Rats, Wistar; Receptors, Neurokinin-1; Tryptophan; Tumor Burden; Tumor Microenvironment | 2013 |
The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Topics: Antineoplastic Agents; Aprepitant; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Morpholines; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Substance P; Tryptophan | 2014 |